{{Drugbox
| IUPAC_name = [2-(4-methoxyphenyl)-3,4-dihydronaphthalen-1-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]methanone
| image = Trioxifene.png
| width = 250

<!--Clinical data-->
| tradename = 
| pregnancy_category = 
| legal_status = 
| routes_of_administration = [[Oral administration|Oral]]

<!--Pharmacokinetic data-->
| bioavailability = 
| metabolism = 
| elimination_half-life = 
| excretion = 

<!--Identifiers-->
| CAS_number = 63619-84-1
| CAS_supplemental = <br />68307-81-3 ([[mesylate]])
| ATC_prefix = none
| ATC_suffix = 
| PubChem = 50139
| ChemSpiderID = 45471
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = R0130F043H
| synonyms = LY-133,314

<!--Chemical data-->
| C=30 | H=31 | N=1 | O=3 
| molecular_weight = 453.57 g/mol
}}

'''Trioxifene''' ([[International Nonproprietary Name|INN]]) (developmental code name '''LY-133,314'''), or as the [[salt (chemistry)|salt]] '''trioxifene mesylate''' ([[United States Adopted Name|USAN]]), is a [[selective estrogen receptor modulator]] (SERM) with [[competitive inhibition|competitive]] [[binding (molecular)|binding]] activity against [[estradiol]] for the [[ERα]] and [[receptor antagonist|antagonistic]] activity against ERα-mediated [[gene expression]], that was under preclinical and clinical development by [[Eli Lilly and Company]] for [[breast cancer]] and [[prostate cancer]],<ref name="pmid14522935">{{cite journal |vauthors=Neubauer BL, McNulty AM, Chedid M, Chen K, Goode RL, Johnson MA, Jones CD, Krishnan V, Lynch R, Osborne HE, Graff JR |title=The selective estrogen receptor modulator trioxifene (LY133314) inhibits metastasis and extends survival in the PAIII rat prostatic carcinoma model |journal=Cancer Research |volume=63 |issue=18 |pages=6056–62 |date=September 2003 |pmid=14522935 |doi= }}</ref> but was abandoned.<ref>Philipp Y. Maximov, Russell E. McDaniel, V. Craig Jordan.  Tamoxifen: Pioneering Medicine in Breast Cancer. Milestones in Drug Therapy.  Springer Science & Business Media, 2013. {{ISBN|9783034806640}}</ref>{{rp|11}}<ref name="Elks2014">{{cite book|author=J. Elks|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA1252|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=1252–}}</ref><ref name="MortonHall2012">{{cite book|author1=I.K. Morton|author2=Judith M. Hall|title=Concise Dictionary of Pharmacological Agents: Properties and Synonyms|url=https://books.google.com/books?id=tsjrCAAAQBAJ&pg=PA281|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-94-011-4439-1|pages=281–}}</ref>

==References==
{{Reflist|2}}


{{Estrogen receptor modulators}}

[[Category:Abandoned drugs]]
[[Category:Aromatic ketones]]
[[Category:Pyrrolidines]]
[[Category:Selective estrogen receptor modulators]]
[[Category:Phenol ethers]]
[[Category:Phenols]]


{{antineoplastic-drug-stub}}